Ardelyx Gets FDA OK for Add-On Therapy for Kidney Disease Patients
By Ben Glickman
Ardelyx has received approval from the U.S. Food and Drug Administration for tenapanor, an add-on treatment for chronic kidney disease patients on dialysis.
The Waltham, Mass.-based biopharmaceutical company said its commercial launch of tenapanor, which goes by brand name Xphozah, was underway with product expected to become available next month.
The company said tenapanor is a phosphate absorption inhibitor which can be given to patients on dialysis with chronic kidney disease who don't have adequate response to phosphate binders or who have intolerance of phosphate binder therapy.
Ardelyx's application for Xphozah was previously rejected by the FDA, but the company appealed its rejection and its resubmission was accepted in May.
The FDA approval was based on a Phase 3 trial of Xphozah which met primary and key secondary endpoints.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 17, 2023 19:29 ET (23:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending